Long-term Immunogenicity and Safety Profile of the Adjuvanted RSVPreF3 Vaccine in Korean Older Adults: A Sub-analysis of a Phase 3 Trial
Infection & Chemotherapy · 2026 · 58 (3) · 332
DOI: 10.3947/ic.2026.0016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection & Chemotherapy, 2026. Verfasst von Seong-Beom Park und 8 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Seoul, Korea. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- GSK, Seoul, Korea.
- GSK Asia House, Singapore.
- GSK, Bangalore, India.
- GSK, Siena, Italy.
- GSK, Wavre, Belgium.
- Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. symonlee@catholic.ac.kr.
ORCID-Profile: Seong-Beom Park, Suryaprakash Mishra, Sang-Kyu Shin, Stebin Xavier, Giulia Zigon, Manuel Zocco, Marie Van Der Wielen, Dong-Gun Lee
Förderung
- GSK
Zitieren
APA
Park, S. B., Mishra, S., Shin, S. K., Xavier, S., Zigon, G., Zocco, M., Van Der Wielen, M., Lee, D. G., & AReSVi-006 study group (2026). Long-term Immunogenicity and Safety Profile of the Adjuvanted RSVPreF3 Vaccine in Korean Older Adults: A Sub-analysis of a Phase 3 Trial. Infection & Chemotherapy, 58(3), 332. https://doi.org/10.3947/ic.2026.0016
Vancouver
Park SB, Mishra S, Shin SK, Xavier S, Zigon G, Zocco M, et al. Long-term Immunogenicity and Safety Profile of the Adjuvanted RSVPreF3 Vaccine in Korean Older Adults: A Sub-analysis of a Phase 3 Trial. Infection & Chemotherapy. 2026;58(3):332. doi:10.3947/ic.2026.0016
BibTeX
@article{Park2026,
author = {Park, Seong-Beom and Mishra, Suryaprakash and Shin, Sang-Kyu and Xavier, Stebin and Zigon, Giulia and Zocco, Manuel and Van Der Wielen, Marie and Lee, Dong-Gun and AReSVi-006 study group, AReSVi-006 study group},
title = {Long-term Immunogenicity and Safety Profile of the Adjuvanted RSVPreF3 Vaccine in Korean Older Adults: A Sub-analysis of a Phase 3 Trial},
journal = {Infection & Chemotherapy},
year = {2026},
volume = {58},
number = {3},
pages = {332},
doi = {10.3947/ic.2026.0016}
}
EUVIMED